# European Respiratory Society Annual Congress 2013 

Abstract Number: 7246<br>Publication Number: P5156


#### Abstract

Group: 4.3. Pulmonary Circulation and Pulmonary Vascular Disease Keyword 1: Pulmonary hypertension Keyword 2: Biomarkers Keyword 3: No keyword


Title: Evaluation of angiopoietin-2 and thrombomodulin as biomarkers for pulmonary hypertension
Mrs. Svenja Lena 1460 Tiede Svenja.Tiede@innere.med.uni-giessen.de ${ }^{1}$, Ms. Insa 1461 Randaxhe insa.xhe@gmx.de ${ }^{1}$, Mr. Thomas 1462 Schmidt Thomas.Schmidt@med.uni-giessen.de ${ }^{1}$, Dr. Henning 1463
Tiede Henning.Tiede@innere.med.uni-giessen.de MD ${ }^{1}$, Prof. Dr Friedrich 1638 Grimminger Friedrich.Grimminger@innere.med.uni-giessen.de MD ${ }^{1}$, Prof. Dr Werner 1465 Seeger Werner.Seeger@innere.med.uni-giessen.de MD ${ }^{1}$, Prof. Dr Hossein Ardeschir 1464 Ghofrani Ardeschir.Ghofrani@innere.med.uni-giessen.de MD ${ }^{1}$ and Prof. Dr Ralph Theo 1466 Schermuly Ralph.Schermuly@innere.med.uni-giessen.de ${ }^{1}$. ${ }^{1}$ University of Giessen Lung Center, Member of the German Lung Center (DZL), Giessen, Germany, 35392 .

Body: Introduction: Angiopoietin-2 (Ang-2) was shown to be increased in plasma of idiopathic pulmonary arterial hypertension (IPAH) patients (Kümpers, P et al. European Heart Journal 2010; 31:2291-2300). On the other hand, thrombomodulin (TM) is significantly decreased in patients with IPAH and with associated forms of pulmonary arterial hypertension (Sakamaki, F et al. Circulation 2000; 102:2720-25). Aims and objectives: To investigate whether Ang-2 and TM have potential as biomarkers for clinical use in Pulmonary Hypertension (PH). Methods: Blood samples from patients with IPAH ( $n=40$ ), PH associated with collagen vascular disease (CVD, $n=40$ ), pulmonary venous hypertension (PVH, $n=40$ ), chronic thromboembolic PH ( $n=40$ ), and non-PH controls ( $n=40$ ) were taken during right heart catheterization. Ang-2 and TM level was measured by ELISA in plasma and correlated with survival and hemodynamics. Results: Ang-2 is significantly higher in plasma from CVD patients (median 4.8 , IQR $10.2 \mathrm{ng} / \mathrm{ml}$ ) compared to non-PH controls (median 3.3, IQR $1.7 \mathrm{ng} / \mathrm{ml}, \mathrm{p}<0.001$ ). Ang-2 plasma levels correlate with pulmonary vascular resistance ( $\mathrm{r}=0.40, \mathrm{p}<0.001$ ) and mixed venous oxygen saturation ( $\mathrm{r}=0.513, \mathrm{p}<0.001$ ). Patients with Ang-2 plasma levels above the median have a poor prognosis ( $1-3-, 5$-year survival $89,86,67$ vs. $97,90,83 \%, p=0.145$ ). There is no difference in plasma levels of TM between the patient groups and non-PH controls, and no association of TM with clinical parameters or prognosis. Conclusions: TM is not a biomarker for diagnosis, prognosis or severity of disease in our cohort. Ang-2 plasma levels are associated with disease severity and prognosis.

